Anti-IKK gamma antibody [72C627] (ab13917)

Overview

• Product nameAnti-IKK gamma antibody [72C627]See all IKK gamma primary antibodies ...
• Description
  Mouse monoclonal [72C627] to IKK gamma
• Tested applicationsWB more details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  This antibody was raised against a His-tagged full-length human IKK3/IKKg protein.

• Positive controlWhole cell lysate from Jurkat cells or NIH 3T3 cells

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: PBS
• Concentration information loading...
• PurityProtein G purified
• Clonality Monoclonal
• Clone number72C627
• IsotypeIgG1
• Research Areas
  • Signal Transduction
  • Signaling Pathway
  • Nuclear Signaling
  • NFkB Pathway

  • Signal Transduction
  • Protein Phosphorylation
  • Ser / Thr Kinases
  • Other Kinases

  • Cardiovascular
  • Atherosclerosis
  • Vascular Inflammation
  • Inflammatory mediators

  • Epigenetics and Nuclear Signaling
  • Nuclear Signaling Pathways
  • NFkB pathway

  • Immunology
  • Innate Immunity
  • TLR Signaling

  • Cell Biology
  • Apoptosis
  • Intracellular
  • NFkB
  • IKK

Applications

Target

• FunctionRegulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity (By similarity). Essential for viral activation of IRF3.
• Tissue specificityHeart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
• Involvement in diseaseDefects in IKBKG are the cause of ectodermal dysplasia anhidrotic with immunodeficiency X-linked (EDAID) [MIM:300291]; also known as hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID). Is a form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by absence of sweat glands, sparse scalp hair, rare conical teeth and immunological abnormalities resulting in severe infectious diseases.
  Defects in IKBKG are the cause of ectodermal dysplasia anhidrotic with immunodeficiency-osteopetrosis-lymphedema (OLEDAID) [MIM:300301].
  Defects in IKBKG are a cause of immunodeficiency NEMO-related without anhidrotic ectodermal dysplasia (NEMOID) [MIM:300584]; also called immunodeficiency without anhidrotic ectodermal dysplasia, isolated immunodeficiency or pure immunodeficiency. Patients manifest immunodeficiency not associated with other abnormalities, and resulting in increased infection susceptibility. Patients suffer from multiple episodes of infectious diseases.
  Defects in IKBKG are the cause of susceptibility to X-linked familial atypical micobacteriosis type 1 (AMCBX1) [MIM:300636]; also known as X-linked disseminated atypical mycobacterial infection type 1 or X-linked susceptibility to mycobacterial disease type 1. AMCBX1 is the X-linked recessive form of mendelian susceptibility to mycobacterial disease (MSMD). MSMD is a congenital syndrome resulting in predisposition to clinical disease caused by weakly virulent mycobacterial species, such as bacillus Calmette-Guerin vaccines and non-tuberculous, environmental mycobacteria. Patients are also susceptible to the more virulent species Mycobacterium tuberculosis.
  Defects in IKBKG are the cause of recurrent isolated invasive pneumococcal disease type 2 (IPD2) [MIM:300640]. Recurrent invasive pneumococcal disease (IPD) is defined as two episodes of IPD occurring at least 1 month apart, whether caused by the same or different serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD the most important known risk factor for subsequent IPD.
  Defects in IKBKG are the cause of incontinentia pigmenti (IP) [MIM:308300]; formerly designed familial incontinentia pigmenti type II (IP2). IP is a genodermatosis usually prenatally lethal in males. In affected females, it causes abnormalities of the skin, hair, eyes, nails, teeth, skeleton, heart, and central nervous system. The prominent skin signs occur in four classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation and dermal scarring.
• Sequence similaritiesContains 1 C2HC-type zinc finger.
• DomainThe leucine-zipper domain and the C2HC-type zinc-finger are essential for polyubiquitin binding and for the activation of IRF3.
• Post-translational
  modificationsPhosphorylation at Ser-68 attenuates aminoterminal homodimerization.
  Polyubiquitinated on Lys-285 through 'Lys-63'; the ubiquitination is mediated by NOD2 and RIPK2 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Polyubiquitinated on Lys-399 through 'Lys-63'; the ubiquitination is mediated by BCL10, MALT1 and TRAF6 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Monoubiquitinated on Lys-277 and Lys-309; promotes nuclear export. Linear polyubiquitinated on Lys-285; the head-to-tail polyubiquitination is mediated by the LUBAC complex. Linear polyubiquitinated on Lys-309; the head-to-tail polyubiquitination is mediated by the LUBAC complex.
  Sumoylated on Lys-277 and Lys-309 by SUMO1; the modification results in phosphorylation of Ser-85 by ATM leading to a replacement of the sumoylation by mono-ubiquitination on these residues.
• Cellular localizationCytoplasm. Nucleus. Sumoylated NEMO accumulates in the nucleus in response to genotoxic stress.

Target information above from: UniProt accession Q9Y6K9 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 8517 Human
  • Entrez Gene: 8517 Human
  • Entrez Gene: 8517 Human
  • Omim: 300248 Human
  • SwissProt: Q9Y6K9 Human
  • SwissProt: Q9Y6K9 Human
  • SwissProt: Q9Y6K9 Human
  • Unigene: 43505 Human

• Alternative names
  IkB kinase associated protein 1 antibody IkB kinase subunit gamma antibody Inhibitor of nuclear factor kappa B kinase subunit gamma antibody

  AMCBX1 antibodyFIP 3 antibodyFIP-3 antibodyFIP3 antibodyFip3p antibodyI kappa B kinase gamma antibodyI-kappa-B kinase subunit gamma antibodyIkB kinase associated protein 1 antibodyIkB kinase gamma subunit antibodyIkB kinase subunit gamma antibodyIkB kinase-associated protein 1 antibodyIKBKG antibodyIKK-gamma antibodyIKKAP 1 antibodyIKKAP1 antibodyIKKG antibodyIncontinentia pigmenti antibodyInhibitor of kappa light polypeptide gene enhancer in B cells kinase gamma antibodyInhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma antibodyInhibitor of nuclear factor kappa B kinase gamma subunit antibodyInhibitor of nuclear factor kappa B kinase subunit gamma antibodyInhibitor of nuclear factor kappa-B kinase subunit gamma antibodyIP 1 antibodyIP 2 antibodyIP antibodyIP1 antibodyIP2 antibodyIPD2 antibodyNEMO antibodyNEMO_HUMAN antibodyNF kappa B essential modifier antibodyNF kappa B essential modulator antibodyNF kappaB essential modifier antibodyNF kappaB essential modulator antibodyNF-kappa-B essential modifier antibodyNF-kappa-B essential modulator antibodyNFkappaB essential modulator antibody

  see all

Anti-IKK gamma antibody [72C627] images

• 

  Western blot - IKK gamma antibody [72C627] (ab13917)
  
  
  Predicted band size : 50 kDa
  
  
  Western blot analysis of 30 µg of total cell lysate from Jurkat (lane 1) and NIH-3T3 (lane 2) cells with ab13917 at 2 ug/ml dilution.